ImmuneResearch strength: PreliminaryEvidence: Preliminary
Chonluten
Chonluten (Glu-Asp-Gly, EDG)
Also known as: EDG
A Khavinson tripeptide sold for lung and mucosal health; patent-level and single-paper evidence.
Overview
Chonluten is marketed for bronchial and gastric mucosa. Its evidence is at the patent and single-paper level from the originating institute, with no human trials.
Mechanism of action
Proposed modulation of epithelial gene expression.
Key studies & citations
- Review2020
Peptide bioregulators: the Khavinson corpus (review)
Single-lineage evidence base.
Stem Cell Reviews and Reports
Frequently asked questions
Is Chonluten studied in humans?
No.